Connect with us
https://tickernews.co/wp-content/uploads/2023/10/AmEx-Thought-Leaders.jpg

Money

Post Market Wrap | ResMed March quarter impacted by input cost inflation and higher freight costsPost Market Wrap |

Published

on

This Post Market Wrap is presented by KOSEC – Kodari Securities

  • Revenue up by 12 percent to US$864 million and income from operations up by 5 percent to US$253 million
  • Revenue and income results miss Bloomberg consensus estimates
  • Gross margin down by 1.4 percent
  • Selling, general and administrative expenses up US$22 million, or 14 percent to US$182 million
  • Cash flow impacted by US$285 million ATO settlement
  •  Balance sheet remains strong with US$1.9 billion in cash and drawdown availability  
  • Management confident that incremental revenue growth will recover in FY23.  

ResMed Inc (‘ResMed’ or the ‘Group’) is a global medical device business that develops, manufactures, distributes and markets medical devices. ResMed  also develops cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing, chronic obstructive pulmonary disease and neuromuscular disease. Resmed’s comprehensive out-of-hospital software platforms are designed to assist caregivers and healthcare professionals keep people healthy in the home or care setting of their choice. The product suite includes air flow generators, diagnostic products and mask systems which are expected to help 250 million lives across 140 countries in 2025. 

Soft Gross Margin in March quarter FY22

ResMed increased revenue by 12 percent to US$864 million for the quarter, compared to the March 2021 quarter, and income from operations increased by 5 percent to US$253 million. Non-GAAP diluted earnings per share was up modestly from US$1.30 per share to US$1.32 per share. These numbers came in below market expectations, based on the important Bloomberg consensus estimates. The market was expecting stronger revenue growth, on the basis that ResMed would benefit from the recall of a competitor product in the US non-invasive ventilator market segment. This market share gain was less than anticipated by investors and can be attributed to ongoing semiconductor supply shortages. Semiconductors or micro-chips are an essential component of ResMed’s medical devices, including ventilators.  

The other disappointing aspect of the March quarter result was the 1.4 percent gross margin contraction to 56.8 percent at March 2022, from 58.2 percent at March 2021. The margindecline is attributable to higher freight and manufacturing costs, partially offset by an increase in average selling prices. A US$12/Euro12 device surcharge introduced in January 2022 has not been enough to offset the cost inflation and higher freight imposts that have emerged since the onset of the global COVID pandemic. Selling, general and administrative expenses increased by 14 percent to US$182 million, compared to the March 2021 quarter.This is an increase of US$22 million from a year ago. Clearly ResMed has not been able to avoid the input cost inflation pressures faced by manufacturers in all parts of the world in recent times.

US$285 million ATO settlement impacts cash flow

Cash from operating activities of US$272 million, for the 9 months to 31 March 2022, represents a decline of US$238 million from US$510 million generated in the previous corresponding 9 months.  The significant decline is primarily due to a US$285 million cash settlement with the Australian Taxation Office in the March quarter. This is the final instalment due to the ATO and follows payments of US$97 million in prior reporting periods, bringing the total amount to US$382 million. The settlement relates to transfer pricing irregularities between 2009 and 2018. The profit impact had previously been recognised in the prior financial year.  

ResMed retains a strong balance sheet and at 31 March had US$1.6 billion available for drawdown plus cash and cash equivalents of US$295 million. 

Looking Ahead

Management continues to refer to the extraordinary demand for sleep and respiratory care products around the globe with double-digit top line revenue growth expected for respiratory care products and high single-digit growth in its software-as-a-service business segment.

Despite the industry-specific and macro-economic environment uncertainty in recent times, demand from patients and healthcare providers remains resilient. Management remainsconfident that as supply chain logistical constraints, including semiconductor component shortages are overcome, lost incremental revenue will be recovered in FY23 and beyond.

This Post Market Wrap is presented by Kodari Securities, written by Michael Kodari, CEO at KOSEC.

"Michael Kodari is one of the world's most consistent, top performing investor. A philanthropist and one of the prominent experts of the financial markets, he has been referred to as ‘the brightest 21st century entrepreneur in wealth management' by CNBC Asia and featured on Forbes. Featured on TV as the "Money Expert", on the weekly Sunday program "Elevator Pitch", he is recognised internationally by governments as he was the guest of honour for the event "Inside China's Future", chosen by the Chinese government from the funds management industry, attended by industry leaders, when they arrived in Sydney Australia, on April 2014. Michael and George Soros were the only two financiers in the world invited and chosen by the Chinese government to provide advice, and their expertise on Chinese government asset allocation offshore. With a strong background in funds management and stockbroking, Michael has worked with some of the most successful investors and consulted to leading financial institutions. He was the youngest person ever to appear on the expert panel for Fox, Sky News Business Channel at the age of 25 where he demonstrated his skillset across a 3 year period forming the most consistent track record and getting all his predictions right over that period. Michael writes for key financial publications, is regularly interviewed by various media and conducts conferences around the world."

Continue Reading

Money

Leading podcast cuts through finance commentary noise

Published

on

With so much financial commentary out there, how do you find clarity?

Wyld Money dives into the world of financial freedom. Whether you’re a seasoned investor or just getting started, join us for actionable tips and tricks to unlock your earning potential, and retire on your own terms.

In this episode, Mark is joined by host of ‘This Is Money’ Podcast, Glen James. #wyld money #trending

Continue Reading

Money

Will slashing immigration curb the housing crisis?

Published

on

The Australian Coalition has revealed its strategy to tackle the housing crisis by reducing migration numbers.

Opposition Leader Peter Dutton’s proposal to cut immigration by a quarter aims to tackle the housing crisis but has been met with skepticism for overlooking deeper structural issues.

Mark Wyld from MW Wealth joins to discuss. #trending #featured #wyld money

Continue Reading

Money

Apple Music’s controversial top 10 albums of all time

Published

on

Apple Music has released its highly anticipated “100 Best Albums of All Time” list, with the top 10 rankings causing a bittersweet symphony of destruction for some music lovers.

The list was curated by a panel of experts and based on various factors including cultural impact, critical acclaim, and commercial success, with the aim to celebrate the most influential and timeless albums across genres.

As reported by the official Apple Music Newsroom blog post, the top ten best albums of all time are the following:

10. Lemonade (2016), Beyoncé

9. Nevermind (1991), Nirvana 

8. Back to Black (2006), Amy Winehouse

7. good kid, m.A.A.d city (2012), Kendrick Lamar

6. Songs in the Key of Life (1976), Stevie Wonder

5. Blonde (2016), Frank Ocean

4. Purple Rain (1984), Prince & The Revolution

3. Abbey Road (1969), The Beatles

2. Thriller (1982), Michael Jackson

1. The Miseducation of Lauryn Hill (1998), Lauryn Hill

In other news, Apple recently became the first company to hit a $3 trillion stock market value, before falling just below that milestone, as reported by Reuters.

Continue Reading

Trending Now